SIG
AST.WS

Stanford Investment Group’s Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) AST.WS Stock Holding History

Stanford Investment Group’s Portfolio AST.WS Stock Details AST.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-4
Closed – – 365
2016
Q4 		$0 Hold
4
– – ﹤0.01% 431
2016
Q3 		$0 Hold
4
– – ﹤0.01% 424
2016
Q2 		$0 Buy
+4
New +$2 ﹤0.01% 374

Other funds holding AST.WS

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AIG
American International Group New York $2.93M AUM 12.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stanford Investment Group's AST.WS Position: Q1 2017 in Review

Stanford Investment Group sold out of Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) in Q1 2017, closing a stake of 4 shares.

Stanford Investment Group first reported a position in AST.WS in Q2 2016 and held it in 3 quarters. The position peaked at $0 in Q4 2016. 35 funds tracked by Wall St. Rank hold AST.WS as of Q1 2017.

  • Stanford Investment Group reported no remaining Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position as of Q1 2017 after selling out during the quarter.
  • Stanford Investment Group sold 4 Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) shares in Q1 2017.
  • Stanford Investment Group first reported a position in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) in Q2 2016 and held it in 3 quarters.
  • Stanford Investment Group's Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position peaked at $0 in Q4 2016.
  • 35 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) as of Q1 2017.

Based on Stanford Investment Group's 13F filing for Q1 2017.